ABBREVIATIONS: AMPK, AMP-activated protein kinase; ANP, atrial natriuretic peptide; GPx1, glutathione peroxidase 1; IL-6, interleukin-6; MMP-2, matrix metallopeptidase 2; MMP-9, matrix metallopeptidase 9; TGF-β, transforming growth factor-β. The present study examined whether metformin treatment prevents isoporterenol-induced cardiac hypertrophy in mice. Chronic subcutaneous infusion of isoproterenol (15 mg/kg/24 h) for 1 week using an osmotic minipump induced cardiac hypertrophy measured by the heart-to-body weight ratio and left ventricular posterior wall thickness. Cardiac hypertrophy was accompanied with increased interleukin-6 (IL-6), transforming growth factor (TGF)-β, atrial natriuretic peptide (ANP), collagen I and III, and matrix metallopeptidase 2 (MMP-2). Coinfusion of metformin (150 mg/kg/24 h) with isoproterenol partially inhibited cardiac hypertrophy that was followed by reduced IL-6, TGF-β, ANP, collagen I and III, and MMP-2. Chronic subcutaneous infusion of metformin did not increase AMP-activated protein kinase (AMPK) activity in heart, although acute intraperitoneal injection of metformin (10 mg/kg) increased AMPK activity. Isoproterenol increased nitrotyrosine levels and mRNA expression of antioxidant enzyme glutathione peroxidase and metformin treatment normalized these changes. These results suggest that metformin inhibits cardiac hypertrophy through attenuating oxidative stress.
INTRODUCTION
Pathological cardiac hypertrophy is an independent risk factor for heart failure [1] . Although hypertension and loss of myocytes following ischemic damage are the leading causes of pathological cardiac hypertrophy [2] , adrenergic overactivation also contributes to hypertrophy. Patients with left ventricular hypertrophy demonstrate increased plasma norepinephrine concentration and enhanced sympathetic nerve activity compared with subjects without hypertrophy [3] [4] [5] . Moreover, adrenergic agonists such as isoproterenol can induce cardiac hypertrophy in experimental animals [6] [7] [8] . Isoproterenol-induced cardiac hypertrophy is a reliable, reproducible, and well-characterized model of pathological cardiac hypertrophy [9, 10] .
The biguanide derivative metformin is one of the most commonly used therapeutic agents for type 2 diabetes [11] . Metformin improves glycemic control via suppression of gluconeogenesis and, to a lesser extent, enhances insulin-mediated glucose uptake in fat and muscle tissue [12] [13] [14] . In addition to its insulin-sensitizing effect, metformin has also been shown to have cardioprotective effects. Patients who received metformin therapy demonstrate significant improvement all-cause and cardiovascular mortality when compared with patients who received sulphonylurea therapy [15, 16] . Metformin treatment also reduces the risk of myocardial infarct in diabetic patients [17] . Recently, metformin was revealed to be an AMP activated protein kinase (AMPK) activator [18] and low doses metformin significantly improves left ventricular function and survival via activation of AMPK [19] . However, the influence of metformin on isoproterenol induced cardiac hypertrophy is unclear. The present study examined whether metformin treatment prevents isoporterenol-induced cardiac hypertrophy.
METHODS

Animals and treatment
Male C57BL/6J mice weighing 20 g were purchased from Samtaco (Seoul, South Korea) and were housed in the animal unit of College of Medicine at Yeungnam University. Mice were housed in a group cage in a room with a 12:12-h light-dark cycle, lights on at 7:00 and off at 19:00. The mice were fed a standard chow diet and given ad libitum access to water. This study was conducted in accordance with the guidelines for the care and use of laboratory animals pro-vided by Yeungnam University. All experimental protocols were approved by the Ethics Committee of Yeungnam University. After intraperitoneal injection of a combination of anesthetics (tiletamine and zolezepam, 25 mg/kg body weight; xylazine, 10 mg/kg body weight), minipumps (Alzet, Cupertino, CA, USA) containing 0.9% saline, metformin (150 mg/kg/24 h), isoproterenol (15 mg/kg/24 h), or metformin with isoproterenol were inserted into skin in the interscapular region. After 1 week, mice were anesthetized and blood samples were collected. After removing blood from hearts, the hearts were weighed. The left ventricles were excised and stored at −80 o C for the measurement of expression of genes and proteins. The chronic effect of metformin on AMPK activation in the heart was measured in mice after inserting minipump (150 mg/kg/day) at 0, 2, 4, 24, and 48 h. The acute effect of metformin on AMPK activation was also measured in mice hearts at 1 h after the intraperitoneal injection of metformin (10 mg/kg). Heart was collected and stored at −80 o C for the measurement of AMPK activity.
Echocardiography
Echocardiograms were conducted on mice anesthetized with intraperitoneal injection of anesthetics after 1 week of saline, isoproterenol, metformin, or isoproterenol with metformin as previously described [6] . Echo imaging was acquired using a Sequoia C512 (Acuson, Mountainview, CA, USA) platform equipped with a 15 MHz linear transducer. Measurements were performed in triplicate using the leading edge convention for myocardial borders, as defined by the American Society of Echocardiography. Posterior wall thickness in diastole was used as an indicator of cardiac hypertrophy.
Real-time polymerase chain reaction (PCR)
Left ventricle of approximately 25 mg was homogenized in TRI reagent (Sigma-Aldrich, St. Louis, MO, USA) using an Ultra-Turrax T25 (Janke & Kunkel, IKA-Labortechnik, Staufel, Germany). RNA was reverse transcribed to cDNA from 1 μg of total RNA using a High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA). Quantitative real-time PCR was performed using the Real-Time PCR 7500 Software system and Power SYBR Green PCR master mix (Applied Biosystems) according to the manufacture's instructions. Expression levels of β-actin were used for sample normalization. The reactions were in- 
Western blotting
Left ventricle was used for measurement of protein level of phosphorylated AMPK (Cell Signaling Technologies, Danvers, MA, USA), AMPK (Cell Signaling Technologies), nitrotyrosine (Upstate Biotechnology, Lake Placid, NY, USA), and glyceraldehyde 3-phosphate dehydrogenase (GAPDH; Santa Cruz Biotechnology, Santa Cruz, CA, USA). Tissue approximately 40 mg was homogenized in a lysis buffer (Invitrogen, Carlsbad, CA, USA) containing 1% NP40, 150 mM NaCl, 5 mM MgCl2, 10 mM HEPES buffer, leupeptin, and pepstatin A. Protein concentration was determined by the Bradford method (BioRad, Hercules, CA, USA). A 30 μg sample of the total protein per lane was separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The separated proteins were then transferred to a 0.45 μm polyvinylidene fluoride membrane (Gelman Sciences, Ann Arbor, MI, USA). After blocking with a solution containing 5% skim milk, 10 mM Tris-HCl (pH 7.4), 150 mM NaCl, and 0.1% Tween 20, the membrane was incubated overnight at 4 o C with a 1：1,000 dilution of the primary antibody. Specific antibody binding was detected using a 1：2,000 dilution of sheep anti-rabbit IgG horseradish peroxidase (Bio-Rad) for 1 h at room temperature and visualized using an enhanced chemiluminescence detection reagent (Millipore, Billerica, MA, USA).
Statistical analyses
The results are expressed as mean±SE. Differences among the groups were assessed via one-way analysis of variance followed by LSD test. All statistical analyses were conducted using SPSS software (SPSS, Chicago, IL, USA).
RESULTS
Heart weight and gene expression
Body weight was not different among the groups (data not shown). Heart weight presented as percentage of heart weight to body weight was increased by isoproterenol infusion that was partially inhibited by coinfusion of isoproterenol with metformin. Metformin alone did not affect heart weight (Fig. 1A) . Left ventricular posterior wall thickness also showed same pattern of changes with heart weight (Fig. 1B) . Since cardiac hypertrophy is known to be associated with increased gene expression of TGF-β, IL-6, ANP, collagen, and MMPs, the gene expression of these factors were measured in this study for the evaluation of cardiac hypertrophy [20, 21] . Isoproterenol infusion increased the mRNA level of TGF-β in heart, which was partially reduced by coinfusion of isoporterenol with metformin ( 2A). The gene expression of IL-6 in heart also showed same pattern of changes with TGF-β; the increased IL-6 mRNA level by isoproterenol was also partially reversed by cotreatment of isoproterenol with metformin (Fig. 2B) . The gene expression of ANP showed this same pattern of changes but it was not statistically significant (Fig. 2C) . Collagen I and III in heart were significantly increased by isoporterenol infusion compared with saline-infused control mice. However, coinfusion of isoproterenol with metformin did not significantly increase the gene expression of collagen I and III in heart. The gene expression of MMP-2 showed the same pattern of changes with collagen I and III. MMP-9 did not differ among the groups (Fig. 3) .
pAM PK levels in heart
Since metformin is known as an AMPK activator, the pAMPK level was measured in heart to investigate whether the effect of metformin was mediated by AMPK activation. Chronic subcutaneous infusion of metformin for 1 week did not affect the pAMPK level in heart, whereas it increased pAMPK level in skeletal muscle (Fig. 4) . Furthermore, subcutaneous infusion of 150 mg/kg/24 h metformin did not increase the pAMPK level at 2, 4, 24 and 48 h in heart (Fig. 5A) . The pAMPK level was also determined in heart after the intraperitoneal injection of 10 mg/kg of metformin in mice and pAMPK level was increased by metformin (Fig.  5B) . This result suggests that although metformin could function as AMPK activator in mice heart, chronic subcutaneous infusion of 150 mg/kg metformin did not activate AMPK in heart.
Nitrotyrosine and glutathione peroxidase
To ascertain the mechanism of the inhibitory effect of metformin on isoproterenol-induced cardiac hypertrophy, protein level of nitrotyrosine and gene expression of glutathione peroxidase 1 were measured in heart. The protein level of nitrotyrosine was increased in isoproterenol-infused heart and coinfusion of isoproterenol with metformin reversed nitrotyrosine level. Measurement of glutathione peroxidase 1 mRNA showed the same pattern of changes (Fig.  6) . These results suggest that isoproterenol infusion increased oxidative stress and metformin treatment sup- 
DISCUSSION
The present study demonstrates that chronic coinfusion of metformin with isoproterenol partially inhibits isoproterenol-induced cardiac hypertrophy that accompanies reduced oxidative stress. Metformin has beneficial effects on heart in human and experimental animals, decreasing cardiovascular mortality and the risk of myocardial infarct in humans and improving left ventricular functions in experimental animals [15] [16] [17] 19] . Although metformin reduces protein synthesis in cardiac myocyte [22] , it is unknown whether metformin inhibits cardiac hypertrophy. Presently metformin partially inhibited isoproterenolinduced cardiac hypertrophy in mice. To our knowledge, this is the first study showing that metformin might also have beneficial effects against cardiac hypertrophy.
Cardiac hypertrophy is associated with increases of cytokines including IL-6, TGF-β, and ANP. Isoproterenol increases IL-6 expression in the heart of rodents [6, 23] and IL-6 transgenic mice display increased left ventricular wall thickness [24] . TGF-β is increased in an animal model of pressure overload hypertrophy [25] and in the hearts of patients with cardiomyopathy [26] . Hypertrophic stimulus also increases ANP expression [27] . Consistent with these previous reports, isoproterenol presently increased the expression of IL-6, TGF-β, and ANP, and metformin partially normalized the increments of these cytokines in heart. Together with reduction of heart weight, attenuated expression of these cytokines in heart supports the therapeutic effect of metformin in cardiac hypertrophy. Furthermore, the increased expression of collagen I and III and MMP-2 by isoproterenol was suppressed by metformin. Since collagen and MMP are involved in cardiac fibrosis and are increased by catecholamine [28, 29] , reduced expression of these genes by metformin also support the beneficial effect of metformin in cardiac hypertrophy.
One possible mechanism involved in the inhibitory effect of metformin on cardiac hypertrophy may be the attenuation of oxidative stress. This notion is supported by the fact that metformin presently reduced isoproterenol-induced increased nitrotyrosine level. Isoproterenol increases inducible nitric oxide synthase (iNOS), leading greater amounts of nitric oxide (NO) compared to other types of NOS, and is induced under various pathologic conditions [30, 31] . NO can be transformed in a reaction with superoxide free radical (O2 − ) to form peroxynitrite (ONOO − ) [32] . Peroxynitrite can nitrate proteins, which can lead to protein dysfunction [32] . One of the few identified nitrated protein is nitrotyrosine, which is a marker of peroxynitrite production and nitrosative stress [33] . In agreement with our result, hypertrophied heart shows increased nitrotyrosine levels and treatment of cardiac hypertrophy is accompanied with reduced oxidative stress including an attenuated nitrotyrosine level [34, 35] . Moreover, isoproterenol presently increased antioxidant enzyme glutathione peroxidase 1, which was normalized by metformin. We speculated that the antioxidant enzyme is increased to protect the heart from hypertrophy and that metformin treatment reduces hypertrophy, which leads to normalization of the antioxidant enzyme.
A variety of effects of metformin are mediated by activation of AMPK. Metformin activates AMPK in hepatocytes which leads to increased lipid oxidation, reduced lipid synthesis and inhibited glucose production [36] . Activation of AMPK by metformin in cardiovascular tissues also mediates a protective effect. Metformin attenuates increased expression of adhesion molecules and apoptosis by high glucose through activation of AMPK in endothelial cells [18] . AMPK activation by metformin also prevents myocardial infarction and reperfusion injury in experimental animal [37, 38] . The antioxidant effect of metformin is also mediated by AMPK activation. Treatment with metformin protects cultured cardiomyocytes from cell death during exposure to hydrogen peroxide via AMPK activation [37] . Metformin reduces intracellular reactive oxygen species induced by palmitate that is mediated by AMPK activation [39] . Presently acute intraperitoneal injection of 10 mg/kg metformin increases AMPK phosphorylation suggesting that metformin can activate AMPK phosphorylation in mice hearts. However, chronic subcutaneous infusion of 150 mg/kg/24 h metformin did not activate AMPK phosphorylation in heart. In agreement with our study, an AMPK-independent effect of metformin was recently reported, in which the administration of 2 mM metformin did not alter AMPK activity in the heart of Sprague-Dawley rats and H9C2 cells although metformin altered fatty acid oxidation and glucose utilization [40] . Metformin also does not increase AMPK activity in mice liver, while it reduces alcohol-induced hepatic lipid accumulation [41] . Whereas metformin alone does not increase AMPK activity, it enhances the activation effect of dehydroepiandrosterone (DHEA) on AMPK activity in mice ovaries [42] . The mechanism of the differential effect of metformin on AMPK activation remains unclear. It is possible that the dose of metformin and the methods of administration are involved. Further studies are needed to clear it.
Overall, metformin partially inhibits isoproterenol-induced cardiac hypertrophy that may be contributed by reduced oxidative stress. This study provides more supportive data concerning the beneficial effect of metformin in terms of the cardiac protective effect on heart.
